Funding
Funding not disclosed
Founders
Product
Problem
Neurodegenerative diseases and neurotrauma, such as spinal cord injury, Parkinson's disease, stroke, traumatic brain injury, hearing loss, and ALS, result in significant functional deficits due to irreversible neuronal damage. Current treatments offer limited regenerative potential, failing to fully restore lost neurological function.
Solution
FortunaFix is developing cell reprogramming technologies aimed at regenerating damaged neural tissue and restoring function in patients with neurodegenerative conditions and neurotrauma. Their approach focuses on directly converting resident cells into functional neurons, bypassing the need for stem cell transplantation or gene therapy. By reprogramming cells within the central nervous system, FortunaFix seeks to promote neurogenesis, re-establish neural circuits, and improve patient outcomes across a range of neurological disorders. Their lead programs target spinal cord injury and Parkinson's disease.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases and neurotrauma, as well as clinicians and researchers specializing in neurology and regenerative medicine.
Features
- Proprietary cell reprogramming factors optimized for neural tissue regeneration
- In vivo reprogramming approach to directly convert resident cells into functional neurons
- Targeted delivery methods to maximize reprogramming efficiency and minimize off-target effects
- Preclinical efficacy data demonstrating functional recovery in animal models of spinal cord injury and Parkinson's disease
- Development pipeline spanning multiple neurological indications, including stroke, traumatic brain injury, hearing loss, and ALS